Clinical Trial Update: A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating combined intravenous plus intracranial administration of ipilimumab and nivolumab in patients with Glioblastoma and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Recurrent Glioblastoma | Phase 1 | Status: RECRUITING